Stockscreener 앱 받기
103.10
1.03%
-1.07
시간 외 거래:
103.00
-0.10
-0.10%
전일 마감가:
$104.17
열려 있는:
$104
하루 거래량:
8.43M
Relative Volume:
1.04
시가총액:
$152.53B
수익:
$17.55B
순이익/손실:
$2.03B
주가수익비율:
75.26
EPS:
1.37
순현금흐름:
$2.72B
1주 성능:
-2.89%
1개월 성능:
-1.74%
6개월 성능:
+13.96%
1년 성능:
+36.56%
1일 변동 폭
$102.32
$104.20
1주일 범위
$102.32
$105.72
52주 변동 폭
$71.88
$107.17
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
103.10 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
133.71 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
381.01 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.54 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.72 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? - MSN
How Is Boston Scientific's Stock Performance Compared To Other Medical Device Stocks? - Barchart.com
Boston Scientific’s longtime DEI, HR leader exits for chief HR role at new company - MassDevice
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scienti - GuruFocus
Before the Bell-Boston Scientific drops on profit miss - Reuters
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scientific Corp (BSX) - GuruFocus
Piper Sandler maintains Boston Scientific stock at Overweight - Investing.com
Continence Care Market Size to Surpass USD 9.54 Billion by 2031 With 5.6% CAGR, Surging Prevalence of Chronic Diseases Propels the Demand | The Insight Partners - GlobeNewswire Inc.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
Boston Scientific ends TAVR sales; J&J shares Monarch robot data - MedTech Dive
Boston Scientific (BSX) Ends Acurate TAVR Program, Shifts Focus to Promising Projects | BSX Stock News - GuruFocus
BSX: Analyst Reiterates Buy Rating for Boston Scientific | BSX S - GuruFocus
In TAVR setback, Boston Sci pulls plug on Acurate valves - BioWorld MedTech
Boston Scientific discontinues Acurate TAVR sales, cites regulatory burden - MassDevice
Boston Scientific Ends ACURATE Valve Sales By Investing.com - Investing.com Canada
Evercore ISI maintains Boston Scientific stock at Outperform - Investing.com
TD Cowen maintains Boston Scientific stock at $115 target By Investing.com - Investing.com South Africa
TD Cowen maintains Boston Scientific stock at $115 target - Investing.com
Boston Scientific (BSX) Discontinues Sales of ACURATE Aortic Valve Systems - GuruFocus
Boston Scientific (BSX) Discontinues Valve Product Amid Regulato - GuruFocus
JPMorgan maintains Boston Scientific stock with $135 target - Investing.com
Citi maintains Buy on Boston Scientific, keeps $125 target - Investing.com
Needham sees Boston Scientific stock as a buy, target at $115 - Investing.com
Boston Scientific (BSX) Discontinues Valve Product Amid Regulatory Challenges | BSX Stock News - GuruFocus
Boston Scientific (BSX) Halts Aortic Valve Systems, Boosting Com - GuruFocus
Boston Scientific (BSX) Halts Global Sales of ACURATE Valve Syst - GuruFocus
Boston Scientific at Bernstein Conference: Strategic Growth and Innovation - Investing.com
Abercrombie & Fitch, Boston Scientific, DoorDash - TradingView
Boston Scientific (BSX) Halts Global Sales of ACURATE Valve Systems | BSX Stock News - GuruFocus
Boston Scientific Ends ACURATE Valve Sales - Investing.com
Boston Scientific shares drop as valve systems are discontinued - Investing.com
Boston Scientific plans changes to expected $200M tariff hit as situation shifts - Yahoo Finance
Boston Scientific (NYSE:BSX) Q1 Earnings: Leading The Medical Devices & SuppliesDiversified Pack - Yahoo Finance
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Citigroup | BSX S - GuruFocus
India Catheters Market Set to Witness Significant Growth - openPR.com
Was Jim Cramer Right About Boston Scientific Corporation (BSX)? - Insider Monkey
Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - GlobeNewswire Inc.
Boston Scientific Acurate neo2 fails to meet non-inferiority in study - MassDevice
July 3rd Options Now Available For Boston Scientific (BSX) - Nasdaq
Investors in Boston Scientific (NYSE:BSX) have seen splendid returns of 182% over the past five years - Yahoo Finance
Boston Scientific (BSX) Target Price Increased by Citi Analyst | - GuruFocus
Boston Scientific (BSX) Target Price Increased by Citi Analyst | BSX Stock News - GuruFocus
Boston Scientific has positive real-world Acurate Prime TAVI data - MassDevice
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago - Yahoo Finance
$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much TodayBoston Scientific (NYSE:BSX) - Benzinga
Boston Scientific’s rating upgraded to A3 by Moody’s Ratings - Investing.com
Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
0.49%
자본화:
|
볼륨(24시간):